Intensity Therapeutics founder and the inventor of Intensity’s DfuseRx platform technology, Lew Bender, discusses the technology that allows the company’s therapeutic products to be injected directly into solid tumors. This innovative process successfully kills tumors and activates an immune response to shut down cancer cells throughout the body.
BioBoss host John Simboli interviewed Intensity Therapeutics’ CEO, Lewis H. Bender in March of 2020. The two discussed the challenges facing a small company developing a unique approach to treating cancer, leadership, partnerships, the potential benefits of the new therapy and the risks & fears that entrepreneurs face when starting a biotech company.
Intensity Therapeutics would like to change the way cancer patients are treated. Treatments such as chemotherapy and radiation impact a patient’s entire body, administering toxic side-effects throughout their system.
In an interview with Drug Development and Delivery, Lewis H. Bender, MA, MBA, says cancer is a local and systemic disease, and new forms of local treatment, such as intratumoral dosing coupled with systemic immunotherapy, are being explored.
Intensity is developing cancer therapies that are delivered directly into tumors, but also stimulate the innate immune system to address the more systemic effects of cancer. We spoke to Lewis Bender, CEO of Intensity, about the company’s platform technology, how it enlists the innate immune system in the battle against cancer, and the thinking behind the company’s approach.
In cancer treatment, chemotherapy and immunotherapy are often seen as completely separate, if complementary, categories of treatments. A tiny biotech out of Westport, CT now wants to shake up that paradigm — and has just raised $6.5 million to do so.
A Westport biotechnology company is looking to redefine what it means to be cured of cancer, developing a treatment that essentially trains the immune system to recognize diseased cells and fight back any recurrence. Intensity Therapeutics began clinical trials this year to test the safety of its treatment, an injection of a drug called INT230-6 directly into a tumor.
Westport’s Intensity Therapeutics gains ground with potential game changing cancer treatment. Armed with a pair of U.S. patents and some $13 million in investments, Intensity Therapeutics Inc. in Westport has started clinical trials on what its founder maintains could be a game-changer in the treatment of cancer.
Intensity Therapeutics said today that the 1st patient was treated in a Phase I/II trial of its intratumorally-administered cancer therapy, INT230-6. The company’s plans to evaluate the safety of its cancer-killing agent in patients with tumors that are treated at the surface of the skin, including breast cancer and melanoma.
Intensity Therapeutics Inc. got its start when Lewis H. Bender, then the CEO of Interleukin Genetics Inc., pondered the treatment failures in checkpoint inhibitors. “I thought, ‘There’s a steering wheel missing,’” he recalls. The key would be to kill tumor cells, but in a way that left them and their cell surface proteins more or less intact.
Intensity Therapeutics has raised USD 1.5m of its planned USD 9m target for its lead preclinical candidate, an intratumoral chemotherapy, said CEO Lewis Bender. By the end of 3Q14, the firm plans to finalize CMOs and CROs for clinical studies, he noted.
Intensity Therapeutics Inc. is developing what could become the first intratumoral chemotherapeutics to achieve better efficacy than systemic chemo by using a formulation technology that enables passive diffusion into tumor cells.